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1634studies reported ideal body mass index or blood
pressure metrics >50%. Presence of ideal status
>50% was noted in 13 of 18 (81%) for smoking
and blood glucose metrics, respectively. Overall,
ideal CVH was very low ranging from 1% to
12% with 11 of 15 (73%) studies reporting #5%
prevalence.
There is convincing evidence that ideal CVH, as
described in the American Heart Association 2020
goal, protects from cardiovascular and all-cause
mortality. Lack of substantial change in ideal CVH
status over the last 2 decades and a projected 6%
improvement by 2020 underscores emergent need for
coordinated efforts to maximize gains in near-term
for sustainable impact (1). The results of our ﬁnd-
ings show that metrics most likely to achieve the
highest yield are healthy diet and physical activity
because they are noted to be least prevalent uni-
formly across all cohorts studied in the United States.
Systematic efforts focusing on these targets will likely
accelerate achieving ideal CVH goals by also indi-
rectly inﬂuencing attainment of favorable status for
body mass index, blood pressure, and fasting glucose
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2595–602.Adverse Lifestyle Trends
Counter Improvements in
Cardiovascular Risk Factor
Management in
Coronary PatientsThree EUROASPIRE (EUROpean Action on Secondary
and Primary prevention In order to Reduce Events)
surveys, conducted between 1999 and 2013 in
Belgium, Czech Republic, Finland, France, Ireland,
the Netherlands, Poland, Slovenia, and United
Kingdom, sought to describe in coronary patients
time trends in lifestyle, risk factor control including
management of diabetes, and cardioprotective med-
ications (1,2). They were undertaken in the same
geographic areas and hospitals including $1 hospital,
offering interventional cardiology and cardiac sur-
gery. Consecutive patients with coronary disease
($18 to <70 years of age) were identiﬁed from hos-
pital discharge lists: 1) coronary artery bypass graft-
ing; 2) percutaneous coronary intervention; 3) acute
myocardial infarction; and 4) unstable angina were
interviewed and examined $6 months later. A
centralized training base of data collectors and stan-
dardized methodologies, including central laboratory
measurements, ensured data quality.
Of 12,775 identiﬁed patients, 8,456 were inter-
viewed (66.2%): 3,320 patients in EUROASPIRE II (1999
to 2000), 2,632 in EUROASPIRE III (2006 to 2007), and
2,513 in EUROASPIRE IV (2012 to 2013). Interview rates
were 67.5%, 63.6%, and 51.4%, respectively. A com-
parison of those attending with those who did not
showed lower participation in women, in younger pa-
tients (except EUROASPIRE II), and those not revas-
cularized. The time trends in lifestyle, medical risk
factors, and prescriptions for cardioprotective medi-
cations are presented in Figures 1A and 1B. The pro-
portion of persistent smokers was similar (52%, 55%,
53%; p ¼ 0.67), whereas obesity (32%, 33%, 39%;
p ¼ 0.007) and self-reported diabetes (19%, 24%, 27%;
p ¼ 0.004) increased. The prevalence of raised blood
pressure ($140/90 mm Hg or $140/80 mm Hg with
diabetes; 54%, 52%, 45%; p ¼ 0.01) and raised low-
density lipoprotein (LDL)-cholesterol ($1.8 mmol/l)
decreased (96%, 80%, 75%; p <0.0001). The use of
high-intensity statins (atorvastatin, 40 to 80 mg, or
rosuvastatin, 20 to 40 mg, or simvastatin, 80 mg)
increased (in EUROASPIRE III to IV 23.0% to 45.1%).
The comparison among 3 surveys over 14 years pro-
vides a unique description of time trends for secondary
prevention. They reveal stagnation in the prevalence
FIGURE 1 Prevalence of Persistent Smoking, Obesity, Raised Blood Pressure, Elevated LDL-Cholesterol, and
Self-Reported Diabetes by Survey and the Use of Antiplatelets, Beta-Blockers, ACE Inhibitors/ARBs and Statins
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(A) *Persistent smoking: self-reported smoking or >10 ppm carbon monoxide in breath in patients reporting to have been smoking in the
month before the index event; †body mass index $30 kg/m2; ‡systolic BP $140 mm Hg and/or diastolic BP $90 mm Hg for patients without
diabetes and systolic BP $140 mm Hg and/or diastolic BP $80 mm Hg for patients with diabetes; §LDL-C $1.8 mmol/l. BP ¼ blood pressure;
95 CI ¼ 95% conﬁdence interval; EA ¼ EUROASPIRE (EUROpean Action on Secondary and Primary prevention In order to Reduce Events);
LDL-C ¼ low-density lipoprotein cholesterol. (B) ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; p ¼ signiﬁcance
for the overall test of equality of prevalences between surveys.
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1635of persistent smokers and increases in obesity and
diabetes. Despite improvements in blood pressure and
LDL-cholesterol control, the adverse lifestyle trends
with a concomitant increase in the prevalence of dia-
betes will counteract some of these gains.
The prevalence of persistent smokers did not
change but most smokers attempted to quit after their
coronary event; however, use of pharmacotherapieswas low. The rising prevalence of obesity brings,
together with an absolute increase in diabetes of
9%, an increased risk of recurrent macrovascular dis-
ease, microvascular disease, and reduction in life ex-
pectancy. Despite an increase in the proportions of
patients achieving the blood pressure and lipid targets
there is further potential to reduce cardiovascular risk
through more effective control. The 2012 Joint
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1636European guidelines on cardiovascular prevention
propose a more conservative blood pressure target
of <140/90 mm Hg, which is still not being achieved,
and an even more rigorous LDL-cholesterol target
of <1.8 mmol/l requiring more intensive management
of both blood pressure and lipids. The risk of recurrent
disease could be further reduced by optimizing the
dose of cardioprotective medications and improving
patient adherence.
The trends in prevalence and control of cardio-
vascular risk factors in EUROASPIRE are in accor-
dance with earlier multinational studies conducted in
Europe and the United States. The results from 6
consecutive National Health and Nutrition Examina-
tion Surveys from 1999 to 2000, to 2009 to 2010 showed
improvement of LDL-cholesterol but in 2009 to 2010
only 58% of individuals with CHD or risk equivalents
had controlled LDL-cholesterol. The new American
College of Cardiology/American Heart Association
guidelines do not have an LDL-cholesterol target and
recommend high-intensity statins for all patients with
coronary heart disease and there has been a 2-fold in-
crease in proportions of patients on high-intensity
statins between EUROASPIRE III and IV.
The main strengths of the EUROASPIRE surveys are
participation by the same countries, geographic re-
gions, and hospitals, and maintaining standardized
methodologies over 14 years, so time trends can be
described with conﬁdence. The geographic regions
studied are not nationally representative and the
standard of care in specialized centers is probably
higher and therefore the reality of secondary pre-
vention practice in general hospitals is likely to be
poorer than described by EUROASPIRE.
In conclusion, time trends from the EUROASPIRE
surveys show the enormous and continuing chal-
lenges in implementing evidence-based prevention
guidelines in clinical practice for coronary patients.
The life-saving treatments for acute coronary artery
disease through angioplasty, stenting and surgery,
and cardioprotective medications must be matched by
modern preventive cardiology programs combining a
professional lifestyle intervention with effective risk
factor control to reduce total cardiovascular risk.
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Ventricular Septal DefectWe read with interest the paper by Menting et al. (1)
recently published in the Journal, about the outcome
of surgical closure of ventricular septal defect (VSD).
We offer the following comment.
